The evidence here is genuinely mixed, and it would be dishonest to give a confident answer in either direction.
One study following women closely through their transition found menopause as a modest turning point toward faster disability accrual. A separate smaller study found the rate of relapses actually fell after menopause, while disability progression continued unchanged, fitting a broader pattern of the disease shifting from relapse-driven biology toward progression-driven biology with age. The largest analysis, involving nearly 500 women and over 13,000 disability measurements, found no inflection point around menopause once age and disease duration were accounted for. Untangling how much of any change is due to hormonal aging versus simple chronological aging has, so far, defeated the available studies.
The disagreement is directly reflected in three different study designs pointing three different directions - worsening, a mixed relapse-versus-progression pattern, and no effect at all - and the field has not resolved which reflects the true underlying relationship.
What the research shows, and which source each finding rests on
In the CLIMB cohort, 124 women followed longitudinally through their transition showed menopause as a modest inflection point toward faster disability accrual (difference 0.076 EDSS units, p=0.024).
In a small Portuguese cohort (n=37), the annualized relapse rate fell after menopause (0.37 to 0.08, p<0.001) while disability progression continued unchanged.
Where the real disagreement is
Each position is shown with its own sources. A position listed here is not necessarily the accepted view.
Menopause as an inflection point toward worsening
researchers in the CLIMB cohort
Close longitudinal follow-up through the actual transition detected a small but statistically significant acceleration in disability accrual timed to menopause.
No true menopause effect once age is controlled
researchers in the largest available cohort
In the largest sample with the most disability measurements, no inflection appeared once age and disease duration were accounted for, suggesting the apparent worsening in smaller studies may reflect ordinary aging rather than menopause specifically.
What would settle it: Cohort designs able to disentangle chronological aging from endocrine staging at the individual level, which current MS cohorts have not managed to do.
What is really going on here
- How can endocrine aging be disentangled from chronological aging in MS cohorts - so far unresolved.
- Would hormone therapy change MS progression around the transition - not addressed by the available cohorts.
Questions for your doctor
- Given the mixed evidence, how are you thinking about monitoring my disability progression through this transition?
- Should we watch my relapse pattern and disability measures more closely during perimenopause?
- Is there a role for hormone-related treatment in my specific MS management?
Questions with no answer yet
Is the disability change seen around menopause in some MS cohorts really caused by the hormonal transition, or is it ordinary aging that happens to occur around the same age?
Partly studiedWhat is known: One cohort found a small but statistically significant acceleration in disability timed to menopause, while the largest available cohort found no inflection once age and disease duration were controlled; disentangling endocrine aging from chronological aging has so far defeated the available cohort designs.
What would test it: A cohort design able to measure hormonal staging independently of chronological age in the same women over time.
Would hormone therapy change the course of MS symptoms or disability progression during the transition?
Not directly studied yetNo research does not mean it does not work, and it does not mean it works. It means nobody has tested it yet.
What is known: None of the available MS-and-menopause cohorts tested hormone therapy as an intervention; they only observed disability and relapse patterns in women who were or were not menopausal.
What would test it: A randomized trial of hormone therapy during the menopause transition with MS relapse rate and disability progression as outcomes.
Does the shift toward fewer relapses but continued disability progression seen after menopause in one small cohort reflect a real menopause-linked change in MS biology, or is it a feature of that particular small sample?
Partly studiedWhat is known: In a small cohort, the annualized relapse rate fell sharply after menopause while disability progression continued unchanged, a pattern the authors linked to the broader, separately documented shift from relapse-driven to progression-driven MS biology with aging generally, but this specific menopause-linked version of the pattern has not been replicated in a larger sample.
What would test it: A larger cohort tracking both relapse rate and disability progression separately through the transition, to replicate or refute the small-cohort pattern.
Sources
- 1.Exploration of changes in disability after menopause in a longitudinal multiple sclerosis cohort.Bove R et al., Mult Scler 2016;22(7):935-943 · Observational study
- 2.The Influence of Menopause in Multiple Sclerosis Course: A Longitudinal Cohort Study.Ladeira F et al., Eur Neurol 2019;80(3-4):223-227 · Observational study
- 3.Menopause does not modify disability trajectories in a longitudinal cohort of women with clinically isolated syndrome and multiple sclerosis followed from disease onset.Otero-Romero S et al., Eur J Neurol 2022;29(4):1075-1081 · Observational study
The letter grades the type of study behind a claim, not the answer itself.
This page is general information based on published research and public sources. It is not medical advice and not a personal assessment, and it does not replace a conversation with your doctor. Peritale is a wellness product, not a medical device, and is not intended to diagnose, treat, cure or prevent any disease. For any medical question, speak with a licensed clinician.
You are not imagining it
In about seven minutes on your phone, Peritale reads five signal systems and maps your symptoms, so you can see that what you feel is real, follow your hormonal transition over time, and walk into your doctor ready to ask for the care you deserve. Your first check is free, no credit card.
Start Free MappingRelated questions
- How do I know if it's ADHD or just perimenopause brain fog?
- Why are so many women getting diagnosed with ADHD in their 40s all of a sudden?
- The stimulant medication helped me focus - doesn't that prove I have ADHD?
- Can perimenopause make an autoimmune condition flare up or get worse?
- Can I take hormone therapy if I have lupus?
- Does hormone therapy help or hurt rheumatoid arthritis around menopause?
- Back to topic: ADHD, autoimmune conditions and histamine